Vaccine Tracking Data—The Next Big Alt Dataset
Investment firms and vendors are searching for signals in healthcare and pharmaceutical data in a bid to get a leg up on a Covid-19 vaccine.
One year ago, no one foresaw the coronavirus pandemic and the havoc it would wreak on every aspect of life and work. As fear and anxiety have spread across the globe, it’s becoming increasingly clear that the only way back to “normal” is the development of a drug that combats the Covid-19 virus.
While ordinary people anxiously await a vaccine, the market is transfixed by the idea of a treatment for this highly contagious disease. Investors are keen to bet on which companies will be successful
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe
You are currently unable to print this content. Please contact info@waterstechnology.com to find out more.
You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@waterstechnology.com
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@waterstechnology.com
More on Data Management
The IMD Wrap: No more turf wars, or why CDOs should heed the Voice of the CTO
Max reviews how our recent Voice of the CTO series has implications for those beyond a firm’s technology function, and how communication and collaboration between tech, data, and leadership will deliver better results.
Dark horse: Deutsche Börse building dark pool
New functionality allowing exchange members to execute sweep trades comes hot on the heels of European rival Euronext launching its own dark pool.
Man Group’s proprietary data platform is a timesaver for quants
The investment firm’s head of data delves into its alt data strategy and use of AI tools to boost quant efficiency.
Waters Wrap: The tough climb for startups
Anthony speaks with two seasoned technologists to better understand why startups have such a tough time getting banks and asset managers to sign on the dotted line.
As crypto ETFs become reality, benchmark providers take center stage
The SEC’s approval of the first spot bitcoin ETFs will expose a growing number of traditional market participants to the maturing world of crypto data, a moment that some—such as CF Benchmarks, BlackRock’s benchmark provider—have been eagerly awaiting.
The IMD Wrap: Blowing tires, engines and budgets in F1 and financial data
There are many similarities between Formula One and financial data—except when it comes to how much you can spend and how much spend contributes to success.
This Week: Overbond, Northern Trust, FIS/Torstone, Trading Technologies, and more
A summary of the latest financial technology news.
FCA declines to directly regulate market data prices
A year-long investigation by the UK regulator to determine whether competition is hindered in the wholesale data markets has concluded with its decision not to directly regulate much-maligned data pricing and licensing structures.
Most read
- Women in Technology & Data Awards 2024: All the winners
- Man Group’s proprietary data platform is a timesaver for quants
- Dark horse: Deutsche Börse building dark pool